Instil Bio (TIL) news
Recent news
ImmuneOnco Biopharmaceuticals (Shanghai) - stock exchange finds ImmuneOnco loan not on normal commercial terms
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (01541.HK) has recently been notified by the Hong Kong Stock Exchange that loan arrangements were not made on normal commercial terms, raising regulatory concerns. This development comes amid ongoing collaboration and financial progress in the company’s…
AInvest Wire · Jul 2, 2026Allogene Therapeutics names Zachary Roberts as CEO
Allogene Therapeutics, Inc. (Nasdaq: ALLO) has appointed Zachary J. Roberts, M.D., Ph.D., as Executive Vice President of Research and Development, a role that includes oversight of the company’s clinical and pre-clinical programs. Dr. Roberts succeeds Rafael Amado, M.D., who has stepped down to…
AInvest Wire · May 28, 2026CBOE Volatility Index up 1.81 points at 20.92
CBOE Volatility Index up 1.81 points at 20.92 The CBOE Volatility Index (VIX), often referred to as the "fear gauge," rose to 20.92 on June 17, 2025, up 1.81 points from its previous close. This increase in volatility reflects investors' heightened concern over the ongoing Israeli-Iran conflict and…
AInvest Wire · Jun 17, 2025ImportantInstil Bio Shares Surge Following Rental Agreement with AstraZeneca
AInvest Wire · Jul 12, 2024ImportantInstil Bio shares fall 7% after reverse split news
AInvest Wire · Dec 5, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.